SDC1 and Miyoshi myopathy: Certain markers, such as CD38, CD138 (SDC1), CD269 (BCMA, TNFRSF17) and CD49d (ITGA4) are characteristic of MM primary cells and HMCLs, making them potential targets for therapy8.